Onconova announces plan for expanding rigosertib clinical trials for patients with MDS
Onconova Therapeutics announced its commercial partner, Pint Pharma, will assist in expanding access to clinical trials studying rigosertib, a novel and targeted anti-cancer compound currently in a Phase 3 study for treatment of MDS, to several selected sites across South America. August 21, 2018